Aadil Sheikh: Menopausal Hormone Therapy and Thrombosis Rethinking Route Dose and Risk
Aadil Sheikh, Hormone Health Specialist | Men’s Health Service Development at London Hormone Clinic, shared a post on LinkedIn about a recent article by him, published in BMJ, adding:
“A rapid response I wrote has been published in the BMJ, responding to the Danish nationwide study on menopausal hormone therapy and thrombosis that made headlines this September.
The study is a genuine contribution. It is the first large registry to isolate modern oestradiol from the older, horse-derived oestrogens most of the historical fear was built on, and it reports absolute risk alongside relative risk, a number needed to harm of 1,055 for a year of oral treatment. Useful, honest numbers.
My response raises three considerations for translating a population-level finding into an individual prescribing decision.
Route and dose are hard to fully separate. Sixty per cent of oral users were on more than 1mg a day, while 56 per cent of transdermal users were on 50 micrograms or less, and the transdermal group was far smaller, 53 clotting events against 661 on oral. Some of what reads as a route effect is partly a dose effect in disguise.
Venous and arterial risk are not the same story. The clotting risk extended across oral doses. The stroke and heart attack risk did not. Oral oestradiol at 1mg or below showed no increase in either. The clinical picture is more precise than a simple oral-versus-transdermal framing allows.
And the progestogens studied are not the one most relevant to a lot of current practice. Eighty per cent of combined regimens used norethisterone. Micronised progesterone was not captured, so the study has little to say about that specific combination directly, though it does not undo the oestrogen-only signal.
The honest conclusion, and the one I end the response on, is that this strengthens the case for transdermal oestradiol in women with real venous risk factors, and for discussing the small excess risk with women on oral treatment. It does not establish that a woman already well on low-dose oral oestradiol, with no relevant risk factors, needs to change route for this reason alone.”
Title: Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study
Author: Aadil Sheikh
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 06:51How YERM Shapes the Careers of Future Hematology Researchers – EHA
-
Nov 20, 2026, 06:44Ann Van De Velde: Emerging Advances in Hemoglobinopathies, Sickle Cell Disease and Rare Anemias
-
Nov 20, 2026, 06:29Markus Müller: ABO Blood Groups and the Rare Bombay Phenotype
-
Nov 20, 2026, 05:57Lance Reed: Specialized Blood Components and Clinical Samples for Research and Diagnostics
-
Nov 20, 2026, 05:41Sundas Anjum: Community Engagement and Blood Donation for Thalassemia Care
-
Nov 20, 2026, 05:24A Celebration of Unity and Dedication in Hemophilia Care – Hemophilia Society Mumbai Chapter
-
Nov 20, 2026, 05:09Farhad Sheikh: Prasugrel vs Ticagrelor in Acute Coronary Syndromes
-
Nov 20, 2026, 05:02Jason Acker: Appointed as the Next Editor-in-Chief of Vox Sanguinis
-
Nov 20, 2026, 04:58Sabri Kemahli: International Society of Hematology Celebrates 80 Years of Hematology with Special Webinar